NEW YORK, July 8, 2016 /PRNewswire/ --
The Biotechnology industry continues to struggle with health care costs andpolitical issues, but some companies continue to impress. Stock-Callers.com takes a look at today's lineup and reviews their performances in the last few trading sessions: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Agios
To access Stock-Callers.com full Notes for free, please visit the links below.
Full Links to Notes
(You may have to copy and paste the links into your browser)
GRFS Notes: http://stock-callers.com/registration/?symbol=GRFS
ACHN Notes: http://stock-callers.com/registration/?symbol=ACHN
AGIO Notes: http://stock-callers.com/registration/?symbol=AGIO
PBYI Notes: http://stock-callers.com/registration/?symbol=PBYI
Barcelona, Spain headquartered specialty biopharmaceutical company, Grifols S.A.'s shares gained 0.67%, closing Thursday's trading session at $16.65. The stock recorded a trading volume of 387,597 shares. Shares of the Company have advanced 7.74% in the previous three months and 3.75% since the start of this year. The stock is trading 5.62% above its 50-day moving average and 5.71% above its 200-day moving average. Additionally, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the U.S., Canada, and globally, have a Relative Strength Index (RSI) of 58.62.
On Thursday, shares in New Haven, Connecticut headquartered biopharmaceutical company, Achillion Pharmaceuticals Inc., recorded a trading volume of 1.96 million shares, which was above their three months average volume of 1.37 million shares. The stock edged 8.69% higher, ending the day at $8.88. The Company's shares have advanced 10.31% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.05% and 6.74%, respectively. Furthermore, shares of Achillion Pharmaceuticals, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the U.S. and globally, have an RSI of 56.11.
Cambridge, Massachusetts-based biopharmaceutical company, Agios Pharmaceuticals Inc.'s stock finished the day 0.93% lower at $42.63 and with a total volume of 441,846 shares traded. Shares of the Company, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the U.S., are trading below their 50-day moving average by 13.58%. The stock has an RSI of 42.18.
Shares in Los Angeles, California headquartered development stage biopharmaceutical company, Puma Biotechnology Inc., ended yesterday's session 5.55% higher at $32.15. The stock recorded a trading volume of 479,216 shares. The Company's shares have advanced 4.21% in the previous three months and are trading 3.42% above their 50-day moving average. Moreover, shares in Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have an RSI of 54.33.
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All